About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Probiotics in Mild Alzheimer's Disease | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGEARLY Phase 1NCT06181513

Probiotics in Mild Alzheimer's Disease

The main objective is to investigate whether administration of probiotics to patients with mild Alzheimer's Disease (AD) reduces neuroinflammation, improves cognitive function and modifies neurophysio...

Lead sponsor: University of Nicosia•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Nicoletta Nicolaou

CONTACT

+35722471903 [email protected]

Sponsors

Lead Sponsor

University of Nicosia

Collaborators

Cyprus Institute of Neurology and Genetics

We will measure specific blood inflammatory markers (primary outcome), neurophysiological activity, cognitive test scores, microbiome composition and dietary habits of participants in the probiotics and placebo group.

Age

65 - 85 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Adults ≥65 years, able to give consent
•Mini-Mental State Examination (MMSE) scores 19-23 (mild AD)
•approximately equal male:female ratio

Exclusion Criteria

•Inability to give consent
•other neurological disease
•relevant psychiatric disorders (e.g. major depression)
•gastrointestinal/metabolic conditions
•history of alcohol/substance dependence
•use of systemic antibiotics in the previous 6 months
•corticosteroid use
•immune stimulating medications
•immunosuppressive agents
•probiotics consumption in the previous 6 months.
•immunosuppression
•structural heart disease
•neutropenia
•radiation
•active intestinal disease

Related studies

Retinal Hyperspectral Imaging in Neurodegenerative Diseases

NCT07545473 · Dementia, Neurodegenerative Diseases, and more

RECRUITINGPhase 3

A Phase 3 Study of NTLA-2001 in ATTRv-PN

NCT06672237 · Neuromuscular Disease, Neuromuscular Diseases (NMD), and more

RECRUITINGPhase 2

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

NCT04838301 · Alzheimer Dementia, Late Onset Alzheimer Disease, and more

RECRUITINGPhase 2

Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients

NCT07338682 · Cognition Disorders in Old Age, Cognitive and Behavioral Impairment

Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia

NCT05741853 · Primary Progressive Aphasia, Dementia, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 5, 2024Terms

Trial snapshot

StatusRECRUITING

PhaseEARLY_PHASE1

Enrollment40

Start dateDec 2022

Last updatedDec 5, 2024

Condition

Neurodegenerative Diseases Cognition Disorders in Old Age

Locations shown

The Cyprus Institute of Neurology and Genetics

Nicosia

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 5, 2024Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions